Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Developer: Eli Lilly and Company Classification: Triple Agonist (GIP/GLP-1/Glucagon receptors) Administration: Once-weekly subcutaneous injection Development Status: Phase 3 clinical trials Expected FDA Approval: Q3 2026 to Q1 2027 Developer: Boehringer Ingelheim Classification: Dual Agonist (Glucagon/GLP-1 receptors) Administration: Once-weekly subcutaneous injection Development Status: Phase 3 clinical trials (SYNCHRONIZE program) Regulatory Status: FDA Breakthrough Therapy designation for MASH Retatrutide emerged from Eli Lillys research into multi-receptor agonism
Moderation is important, and many prescribers recommend minimizing or avoiding alcohol during the initial months of treatment
Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines
Please let us know the product you're interested in, and our sales team will provide you with detailed information
US$ 24.96
US$ 22.55
US$ 27.23
US$ 29.32
US$ 23.89
